IRRAS (OM:IRRAS) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

IRRAS Stoklara Genel Bakış

IRRAS AB (publ), a medical device company, focuses on the delivery of medical solutions to enhance the lives of critically ill patients worldwide.

Şirket hakkında

IRRAS temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Ödüller

Gelirin yılda 62.97% oranında artması öngörülüyor

Risk Analizi

1 yıldan az nakit akışı var

Anlamlı bir piyasa değeri yok ( SEK182M )

Anlamlı bir geliri yok ( SEK43M )

Hissedarlar geçen yıl sulandırıldı

+ 1 daha fazla risk

IRRAS AB (publ) Rakipler

Medclair

NGM:MCLR

SEK 144.4m

Prolight Diagnostics

NGM:PRLD

SEK 96.8m

Luxbright

OM:LXB

SEK 109.9m

Nanexa

OM:NANEXA

SEK 230.7m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti IRRAS
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	SEK 0.16
52 Haftanın En Yüksek Seviyesi	SEK 0.63
52 Haftanın En Düşük Seviyesi	SEK 0.11
Beta	1.73
11 Aylık Değişim	-6.47%
3 Aylık Değişim	-10.39%
1 Yıllık Değişim	-64.36%
33 Yıllık Değişim	-97.58%
5 Yıllık Değişim	-99.58%
Halka arzdan bu yana değişim	-99.57%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	IRRAS	SE Medical Equipment	SE Pazar
7D	-1.1%	-0.6%	0.8%
1Y	-64.4%	21.2%	25.1%

Getiri vs. Endüstri: IRRAS geçen yıl % 21.2 oranında getiri sağlayan Swedish Medical Equipment sektörünün gerisinde kaldı.

Getiri vs Piyasa: IRRAS geçen yıl % 25.1 oranında getiri sağlayan Swedish Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is IRRAS's price volatile compared to industry and market?
IRRAS volatility
IRRAS Average Weekly Movement	5.7%
Medical Equipment Industry Average Movement	7.4%
Market Average Movement	5.5%
10% most volatile stocks in SE Market	11.6%
10% least volatile stocks in SE Market	3.2%

İstikrarlı Hisse Senedi Fiyatı: IRRAS son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: IRRAS 'nin haftalık oynaklığı ( 6% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2011	47	Will Martin	www.irras.com

IRRAS AB (publ) Temel Bilgiler Özeti

IRRAS'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
IRRAS temel i̇stati̇sti̇kler
Piyasa değeri	SEK 181.75m
Kazançlar(TTM)	-SEK 196.40m
Gelir(TTM)	SEK 43.10m

4.2x

P/S Oranı

-0.9x

F/K Oranı

IRRAS aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
IRRAS gelir tablosu (TTM)
Gelir	SEK 43.10m
Gelir Maliyeti	SEK 44.03m
Brüt Kâr	-SEK 935.00k
Diğer Giderler	SEK 195.47m
Kazançlar	-SEK 196.40m

Son Raporlanan Kazançlar

Jun 30, 2023

Sonraki Kazanç Tarihi

Feb 21, 2024

Hisse başına kazanç (EPS)	-0.17
Brüt Marj	-2.17%
Net Kâr Marjı	-455.71%
Borç/Özkaynak Oranı	0%

IRRAS uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

IRRAS Stoklara Genel Bakış

Ödüller

Risk Analizi

IRRAS AB (publ) Rakipler

NGM:MCLR

SEK 144.4m

NGM:PRLD

SEK 96.8m

OM:LXB

SEK 109.9m

OM:NANEXA

SEK 230.7m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

IRRAS AB (publ) Applies for Its Shares to Be Delisted from Nasdaq Stockholm

IR Holding Bidco Inc. Requests Compulsory Buy-Out and IRRAS Applies for Delisting

Insufficient new directors

Legacy Capital Partners S.C.A. I, Spetses Investments Ltd, Bacara Holdings Limited, Lexington Holding Assets Ltd and Panormos Holding Limited completed the acquisition of a 26.6% stake in IRRAS AB (publ) (OM : IRRAS).

IRRAS AB (publ) to Report Q2, 2023 Results on Aug 04, 2023

IRRAS AB (publ) Provides Sales Guidance for the Second Quarter of 2024

Recent updates

IRRAS AB (publ) Applies for Its Shares to Be Delisted from Nasdaq Stockholm

IR Holding Bidco Inc. Requests Compulsory Buy-Out and IRRAS Applies for Delisting

Insufficient new directors

Legacy Capital Partners S.C.A. I, Spetses Investments Ltd, Bacara Holdings Limited, Lexington Holding Assets Ltd and Panormos Holding Limited completed the acquisition of a 26.6% stake in IRRAS AB (publ) (OM : IRRAS).

IRRAS AB (publ) to Report Q2, 2023 Results on Aug 04, 2023

IRRAS AB (publ) Provides Sales Guidance for the Second Quarter of 2024

IRRAS AB (Publ) Announces Resignation of Eva Nilsagård as a Board Member

Price target increased by 69% to kr5.00

First quarter 2023 earnings released: kr0.07 loss per share (vs kr0.42 loss in 1Q 2022)

Consensus revenue estimates decrease by 25%

Full year 2022 earnings released: kr0.52 loss per share (vs kr1.89 loss in FY 2021)

IRRAS AB (publ) Announces That the Publication of the First Comparative Study

IRRAS AB (publ) to Report Q4, 2023 Results on Feb 21, 2024

IRRAS Receives US FDA 510(K) Clearance for Its Next Generation IRRAflow Control Unit

Is IRRAS (STO:IRRAS) In A Good Position To Deliver On Growth Plans?

IRRAS AB (publ) SHARE AK to Be Deleted from OTC Equity

Price target increased to kr5.00

Insufficient new directors

IRRAS AB (publ) to Report Q4, 2022 Results on Feb 22, 2023

IRRAS AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 214.599618 million.

Irras Announces First Patient Treatments At Mount Sinai Health System in New York as Part of the Dive Study

Second quarter 2022 earnings released: kr0.46 loss per share (vs kr0.40 loss in 2Q 2021)

IRRAS AB Provides Revenue Guidance for the Year 2022

Insufficient new directors

Price target decreased to kr7.00

IRRAS AB (publ) Announces First Global Patient Treatment with Next-Generation IRRAflow® System

IRRAS AB (publ) Launches Next-Generation of the IRRAflow System in the United States

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

IRRAS AB (publ) to Report Q2, 2022 Results on Jul 22, 2022

Consensus revenue estimates fall by 32%

IRRAS Announces Presentation of the Dataset to Date to Document Clinical Outcomes Using Its IRRAflow system

IRRAS Announces First Patients Enrolled in ACTIVE Study, a Comparative Clinical Trial Designed to Confirm IRRAflow's Efficacy to Traditional Passive Drainage

Here's Why We're A Bit Worried About IRRAS' (STO:IRRAS) Cash Burn Situation

Third quarter 2021 earnings released: kr0.34 loss per share (vs kr0.47 loss in 3Q 2020)

IRRAS AB (publ) Demonstrates Ability to Treat Pyogenic Ventriculitis Through Targeted Delivery of Antibiotics in Case Series Published in Neurosurgery Open

We Think IRRAS (STO:IRRAS) Needs To Drive Business Growth Carefully

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.55 loss in 2Q 2020)

IRRAS AB Receives Extension of Its MDSAP Certification and Scope Expansion of MDSAP & ISO 13485:2016 Certifications

IRRAS AB Announces Publication of A Case Report from Buffalo General Medical Center, Highlights Clinical Superiority of IRRAflow Treatment Versus Traditional Drainage

Price target decreased to kr8.70

First quarter 2021 earnings released: kr0.58 loss per share (vs kr1.19 loss in 1Q 2020)

We Think IRRAS (STO:IRRAS) Needs To Drive Business Growth Carefully

Irras Announces the Recruitment of Sten Gustafsson as Director of Investor Relations

Analysts update estimates

Full year 2020 earnings released: kr24.64 loss per share (vs kr5.61 loss in FY 2019)

Price target lowered to kr10.25

Earnings beat expectations, revenue disappoints

New 90-day low: kr6.11

Price target lowered to kr11.00

Analysts update estimates

Irras AB Announces an Exclusive Distribution Agreement with Medical Innovation Solutions

IRRAS AB Announces Exclusive Distribution Agreement with Anade SA

New 90-day high: kr9.00

IRRAS AB Announces an Exclusive Distribution Agreement with KM Innovations BV

IRRAS AB Announces Breakthrough Technology Purchasing Agreement with Premier for Hummingbird ICP Monitoring Products

Third quarter 2020 earnings released: kr0.47 loss per share

Revenue and earnings miss expectations

Analysts lower revenue estimates to kr10.7m

Price target lowered to kr12.00